A Phase 1, Randomized, Parallel-Design, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2015
Price : $35 *
At a glance
- Drugs Etanercept (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Protalix Biotherapeutics
- 05 Oct 2015 Results published in Protalix media release.
- 05 Oct 2015 Status changed from recruiting to completed, as reported by Protalix Bio Therapeutics media release.
- 07 May 2015 Status changed from planning to recruiting, as reported by Portalix Bio Therapeutics media release.